Sio Congress, mepolizumab changes clinical history of nasal polyposis

Among the issues at the center of the 110th National Congress of the Italian Society of Otolaryngology and Head and Neck Surgery – SIO, the theme is “The Future is Listening”, chronic rhinosinusitis with nasal polyposis (CRSwNP) for which the monoclonal antibody mepolizumab represents a new therapeutic option. All patients with severe, relapsing CRSwNP, starting from 150 eosinophils, can benefit from the drug with the advantage of a mechanism of action that acts precisely on inflammation.